Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 8/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 3/20 | 0.55 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26756135 | 0.88 | AR (0.57) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL26637734 | 0.83 | GRM6 (0.52) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL6647319 | 0.82 | AR (0.52) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL6160814 | 0.82 | GRM6 (1.00) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL25758961 | 0.82 | GRM6 (0.76) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL11634973 | 0.82 | MAPT (0.63) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL4217459 | 0.82 | GRM6 (1.00) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL26756120 | 0.81 | ALDH1A1 (0.54) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL26756189 | 0.81 | PKM (0.51) | GRM6MAPTALDH1A1GAAHPGD | |
| SCHEMBL31464161 | 0.79 | GRM6 (0.71) | GRM6MAPTALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024233595-A1 | LIGHT ACTIVATED CLEANING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240374769-A1 | LIGHT ACTIVATED CLEANING COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2024-11-14 | — | — | US | claimed |
| CN-117924314-A | Preparation method of Rayleigh Lu Geli intermediate | 浙江东亚药业股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-20250368660-A1 | Thienopyrimidine derivative | TAKEDA PHARMACEUTICALS CO (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4634195-A1 | PROCESS FOR THE PREPARATION OF RELUGOLIX | Medichem, S.A. (ES) | 2025-10-22 | — | — | EP | disclosed |
| EP-4004001-B1 | SUBSTITUTED PYRIMIDINEDIONE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2025-09-03 | — | — | EP | disclosed |
| US-20250250281-A1 | PROCESS FOR PREPARATION OF RELUGOLIX | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-08-07 | — | — | US | disclosed |
| US-12325714-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-10 | — | — | US | disclosed |
| CN-119859135-A | Rayleigh Lu Geli intermediate and preparation method thereof | 浙江工业大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-119859152-A | Rayleigh Lu Geli and three-step synthesis method thereof | 诚达药业股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119859136-A | Rayleigh Lu Geli key intermediate compound G and preparation method thereof | 诚达药业股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-6180792-B1 | DRUGS, ANTISECRETORY AGENTS AND HORMONE INHIBITORS FOR LH-RH | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-30 | — | — | US | disclosed |
| WO-2000056739-A1 | THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-28 | — | — | WO | disclosed |
| EP-1004585-A1 | THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH | Takeda Chemical Industries, Ltd. (JP) | 2000-05-31 | — | — | EP | disclosed |
| US-6048863-A | SEXUAL DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| US-5817819-A | GONADOTROPIN-RELEASING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0808317-A1 | THIENOPYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-11-26 | — | — | EP | disclosed |
| EP-0756599-A1 | BICYCLIC THIOPHENE DERIVATIVES AND USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 1997-02-05 | — | — | EP | disclosed |
| WO-1996024597-A1 | THIENOPYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-15 | — | — | WO | disclosed |
| WO-1995028405-A1 | BICYCLIC THIOPHENE DERIVATIVES AND USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368660-A1 | Thienopyrimidine derivative | GNRHR, KISS1R, MC4R | GRM6 288/4885MAPT 4161/4885ALDH1A1 2373/4885 |
| US-12325714-B2 | Compositions of thienopyrimidine derivatives | GNRHR, KISS1R, NR5A1 | GRM6 287/4885MAPT 4135/4885ALDH1A1 2438/4885 |
| US-20250250281-A1 | PROCESS FOR PREPARATION OF RELUGOLIX | RDX, RBX1, PHAX | GRM6 1581/4885MAPT 1873/4885ALDH1A1 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.